Skip to Main Content
An official website of the United States government

Primary treatment assignment, time-to-treatment, and prostate cancer outcomes in PLCO

Principal Investigator

Name
Dudith Pierre-Victor

Degrees
MPH, PhD

Institution
National Cancer Institute

Position Title
Cancer Prevention Fellow

Email
dudith.pierre-victor@nih.gov

About this CDAS Project

Study
PLCO (Learn more about this study)

Project ID
PLCO-273

Initial CDAS Request Approval
May 3, 2017

Title
Primary treatment assignment, time-to-treatment, and prostate cancer outcomes in PLCO

Summary
Prostate cancer is the second leading cancer and the third leading cause of cancer death among men in the United States. Approximately, 4 out of 10 cancer patients have a pre-existing condition. Comorbidities are associated with cancer-related and non-cancer related mortality. Prostate cancer patients have multiple treatment options, and treatment choices are influenced by for several factors, including tumor stage, patient’s age, and comorbidity. Among prostate cancer patients, delays from the time of confirmed diagnosis to first treatment are common; primary treatment varies among patients with the same prostate tumor stage. While several treatment options are available, the need to identify the best treatment for those with comorbidities is still present. Additionally, the effect of treatment delays and primary treatment choice on prostate cancer and other-cause mortality remains unclear. We wish to use the prostate cancer component of the PLCO in order to identify factors associated with primary treatment assignment and delays in treatment (stratified by disease stage) and to further understand how comorbidity, time-to-treatment, and primary treatment impact prostate cancer outcomes.

Aims

1. Investigate the effect of time-to-treatment and primary treatment on prostate cancer mortality and other cause mortality.
2. Identify socio-demographic factors and clinical characteristics associated with treatment delays among men with prostate cancer.
3. Assess clinical and socio-demographic factors associated with primary treatment assignment among men with prostate cancer.
4. Determine whether primary treatment assignment is associated with other cause mortality.
5. Examine treatment modalities and cancer outcomes among men with the same prostate cancer stage at diagnosis by comorbidity profile.

Collaborators

Dr. Paul Pinsky, NCI/DCP, Early Detection Research Branch
Dr. Iman K. Martin, NCI/DCP, Community Oncology and Prevention Trials Research Group
Dr. Kevin Dodd, NCI/DCP, Biometry Research Group

Related Publications